We report a case of pyoderma gangrenosum (PG) caused by secukinumab, which was successfully treated with risankizumab. We also reviewed reported cases of PG caused by interleukin (IL)-17 inhibitors. The clinical course of this case indicates that IL-23 may play an important role in the pathogenesis of PG and therefore IL-23-targeting therapies may be a treatment option for PG.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ced.15183 | DOI Listing |
Publication Analysis
Top Keywords
pyoderma gangrenosum
8
gangrenosum caused
8
caused secukinumab
8
secukinumab treated
8
treated risankizumab
8
risankizumab case
4
case report
4
report literature
4
literature review
4
review report
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!